Axsome Therapeutics
AXSM
$207.75
+12.94%
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders, operating within the high-risk, high-reward biotechnology industry. The company has established itself as a commercial-stage entity with a differentiated portfolio targeting conditions with significant unmet medical needs, such as major depressive disorder and narcolepsy. The current investor narrative is driven by the company's transition from a clinical-stage developer to a commercial entity, with recent quarterly revenue showing substantial year-over-year growth, sparking debates about its path to profitability, the sustainability of its launch trajectories, and the potential of its broader pipeline to drive future value.…
AXSM
Axsome Therapeutics
$207.75
AXSM 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axsome Therapeutics's 12-month outlook, with a consensus price target around $270.07 and implied upside of +30.0% versus the current price.
Average Target
$270.07
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$166 - $270
Analyst target range
Analyst coverage is robust with 7 firms providing estimates, and institutional sentiment is uniformly bullish, as evidenced by recent actions from firms like Guggenheim, RBC Capital, and UBS all maintaining Buy or Outperform ratings. The consensus revenue estimate for the forward period is approximately $3.32 billion, with a wide range from a low of $2.78 billion to a high of $3.95 billion, indicating significant variance in growth expectations among analysts. While a specific consensus price target is not provided in the data, the high/low revenue estimate spread of over $1.1 billion signals substantial uncertainty regarding the commercial uptake and peak sales potential of Axsome's portfolio. The pattern of reiterated bullish ratings following quarterly results suggests analysts are endorsing the current growth trajectory, but the wide target range underscores the stock's sensitivity to quarterly execution and pipeline updates.
Bulls vs Bears: AXSM Investment Factors
The evidence currently leans bullish, driven by the undeniable strength of Axsome's commercial launch, with 65% YoY revenue growth and strong technical momentum. The bear case is grounded in valid concerns about profitability, leverage, and the rich valuation that demands sustained hyper-growth. The single most important tension in the investment debate is the race between accelerating revenue growth and the clock on cash burn and leverage. If revenue growth can continue to accelerate towards the high end of analyst targets ($3.95B), the stock will likely re-rate higher. However, if growth plateaus or decelerates even slightly, the combination of high leverage, cash burn, and a demanding sales multiple could trigger a sharp correction.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $196.0 million grew 65.03% YoY, accelerating sequentially from Q3's $171.0 million. This demonstrates successful commercial execution for its CNS therapies, validating the transition from a clinical-stage to a commercial-stage company.
- Strong Technical Momentum: The stock is up 76.42% over the past year and trades at 97% of its 52-week high of $191.5. It has shown strong relative strength, outperforming the S&P 500 by 45.8 percentage points over the same period, indicating powerful investor conviction in the growth story.
- High Gross Margin Profile: The company boasts a pharmaceutical-grade gross margin of 93.71% (Q4 2025), providing a robust foundation for future profitability as revenue scales and operating leverage kicks in. This margin is consistent with successful commercial biotechs.
- Unanimous Analyst Bullishness: All 7 covering analysts maintain Buy or Outperform ratings, with forward revenue estimates averaging $3.32 billion, implying massive growth from the current ~$200M quarterly run-rate. This strong institutional endorsement supports the growth narrative.
Bearish
- Persistent Unprofitability & Cash Burn: Despite high revenue growth, the company posted a Q4 2025 net loss of $28.6M and has negative TTM free cash flow of -$93.8M. The path to GAAP profitability remains uncertain and dependent on continued high sales growth to offset substantial operating expenses.
- High Financial Leverage: The debt-to-equity ratio stands at a concerning 2.73, indicating significant leverage on the balance sheet. While cash is substantial at $322.9M, this debt burden increases financial risk and interest expense, pressuring the path to net income positivity.
- Valuation Remains Rich on Sales Basis: A trailing PS ratio of 14.23x and EV/Sales of 14.47x are high for a company still reporting losses, demanding near-perfect execution of its $3.3B forward revenue target. Any growth deceleration could trigger severe multiple compression.
- Extreme Short Interest: The short ratio of 4.92 indicates very high short interest, representing a significant overhang of skeptical investors betting against the story. This can amplify downside volatility on any negative news or earnings miss.
AXSM Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a 1-year price change of +76.42%, significantly outperforming the broader market. As of the latest close at $185.96, the price is trading near the top of its 52-week range, approximately 97% of the way from its 52-week low of $96.09 to its high of $191.5, indicating strong momentum but also potential overextension. Recent short-term momentum is robust, with the stock up 14.95% over the past month, which accelerates the longer-term trend; this is further supported by a 6-month gain of 43.54%. However, the stock's beta of 0.474 suggests it has been significantly less volatile than the market, which is atypical for a biotech and may reflect a maturing commercial profile or reduced binary event risk. Key technical support is anchored at the 52-week low area near $96, while immediate resistance sits just above at the 52-week high of $191.5; a decisive breakout above this level could signal a new leg higher, whereas a failure here might lead to consolidation. The stock's low beta implies lower relative risk for position sizing, but its proximity to all-time highs demands careful monitoring for any signs of a reversal.
Beta
0.47
0.47x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$96-$217
Price range past year
Annual Return
+85.0%
Cumulative gain past year
| Period | AXSM Return | S&P 500 |
|---|---|---|
| 1m | +22.9% | +10.5% |
| 3m | +12.8% | +3.9% |
| 6m | +53.9% | +5.4% |
| 1y | +85.0% | +29.6% |
| ytd | +16.3% | +5.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXSM Fundamental Analysis
Revenue growth is explosive, with Q4 2025 revenue reaching $196.0 million, representing a year-over-year increase of 65.03%. This growth is accelerating on a sequential basis from Q3's $171.0 million, indicating successful commercial execution for its lead products. The revenue is almost entirely ($194.7 million) derived from product sales, confirming the company's transition to a commercial entity. Despite strong top-line growth, profitability remains elusive; Q4 2025 reported a net loss of $28.6 million, though this marks a significant improvement from a net loss of $74.9 million in the year-ago quarter. The gross margin is exceptionally high at 93.71%, typical for a pharmaceutical company, but operating expenses are consuming revenues, resulting in an operating loss of $29.4 million for the quarter. The balance sheet shows a mixed financial health picture: the company holds a substantial cash position of $322.9 million as of Q4 2025, but it also carries a high debt-to-equity ratio of 2.73, indicating significant leverage. Trailing twelve-month free cash flow remains deeply negative at -$93.8 million, and the current ratio of 1.55 suggests adequate short-term liquidity, though the company is still reliant on external financing to fund its operations and growth initiatives.
Quarterly Revenue
$195999000.0B
2025-12
Revenue YoY Growth
+0.65%
YoY Comparison
Gross Margin
+0.93%
Latest Quarter
Free Cash Flow
$-93814000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXSM Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 14.23x, while the forward-looking metric, EV/Sales, is 14.47x, indicating the market expects revenue growth to continue at a steady pace with little multiple expansion anticipated. Compared to industry averages, data is not available in the provided dataset for a direct sector PS comparison; however, the valuation must be assessed on its own growth merits. Historically, the stock's own PS ratio has compressed dramatically from levels above 40x in early 2024 to the current ~14x, reflecting the company's transition from a pure pipeline story to a commercial one with measurable sales. Trading near the lower end of its own historical PS band suggests the market may be applying a more conservative multiple to its now-realized revenues, potentially offering a value opportunity if growth persists, but also pricing in execution risks and the path to profitability.
PE
-49.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -81x~-9x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on the company's path to sustainability. Despite $196M in quarterly revenue, Axsome continues to burn cash, with negative TTM FCF of -$93.8M and a Q4 net loss of $28.6M. The high debt-to-equity ratio of 2.73 introduces significant financial risk and interest expense pressure. Furthermore, the company's valuation (14.2x PS) is entirely predicated on revenue growth continuing at its current 65% YoY pace; any stumble in commercial execution would immediately threaten its ability to fund operations without further dilutive or debt-financed capital raises.
Market & Competitive Risks stem from its premium valuation in a sector sensitive to growth disappointments. Trading at a PS multiple of 14.2x while still unprofitable leaves the stock vulnerable to sector-wide de-rating if investor sentiment shifts away from growth-at-any-price stories. The low beta of 0.474 is atypical for a biotech and may not protect against idiosyncratic, company-specific setbacks. Competitive threats in the CNS therapy space are ever-present, and the wide $1.1B spread in analyst revenue estimates underscores the uncertainty around Axsome's ability to capture and maintain market share.
Worst-Case Scenario involves a combination of a growth slowdown and a financing crunch. A quarterly revenue miss triggers a loss of investor confidence, leading to a severe de-rating of the PS multiple from 14x towards single digits. Concurrently, high short interest (ratio 4.92) fuels a downward spiral. With cash burn continuing and high debt limiting flexibility, the company is forced to raise capital on unfavorable terms. This could realistically drive the stock back towards its 52-week low of $96.09, representing a downside of approximately -48% from the current price of $185.96.
